What the “therapeutic ladder” for AD in the pediatric and adolescent group, and what is the trigger for systemic immunotherapy? Where does dupilumab-mediated, type 2 cytokine-targeting fit into your approach to AD in the younger population?
What the “therapeutic ladder” for AD in the pediatric and adolescent group, and what is the trigger for systemic immunotherapy? Where does dupilumab-mediated, type 2 cytokine-targeting fit into your approach to AD in the younger population?
Presenter
Clinical Assistant Professor of Dermatology and Pediatrics
Feinberg School of Medicine
Northwestern University
Chicago, Illinois